Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 18, Issue SUPPL. 2, 2007, Pages

  Zucca, E ^a,b  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CD20 ANTIBODY; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; PROTON PUMP INHIBITOR; RITUXIMAB;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG RESPONSE; ENDOSCOPIC ECHOGRAPHY; ERADICATION THERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH BIOPSY; STOMACH LYMPHOMA; STOMACH SURGERY; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HELICOBACTER INFECTIONS; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; NEOPLASM STAGING; RISK ASSESSMENT; STOMACH NEOPLASMS;

EID: 54349117758     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm039     Document Type: Article

References (8)

1. Farinha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005; 23 (26): 6370-6378.
2. Sackmann M, Morgner A, Rudolph B et al: Regression of gastric MALT lymphoma after eradication of Helicobacter pylon is predicted by endosonographic staging. Gastroenterology 1997; 113: 1087-1090.
3. Levy M, Copie-Bergman C, Traulle C et al. Conservalve treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: Predictive factors of response and outcome. Am J Gastroenterol 2002; 97: 292-297.
4. Bertoni F, Zucca E. State-of-the-art therapeutics: Marginal-zone lymphoma. J Clin Oncol 2005; 23 (26): 6415-6420.
5. Koch P, del Valle F, Berdel WE et al. Primary gastrointestinal non-Hodgkin's lymphoma II: Combined surgical and conservative or conservative management only in localized gastric lymphoma. Results of the prospective German multicenter study (GIT NHL 01/92). J Clin Oncol 2001; 19: 3874-3883.
6. Aviles A, Nambo MJ, Neri N et al. Mucosa-associated lymphoid tissue (MALT) lymphoma, of the stomach. Results of a controlled clinical trial. Med Oncol 2005; 22: 57-62.
7. Koch P, Probst A, Berdel WE et al. Treatment results in localized primary gastric lymphoma: Data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005; 23 (28): 7050-7059.
8. Martinelli G, Laszlo D, Ferred AJ et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979-1983.